AbbVie Inc's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Ebitda" stands at 12.72 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the lowest value since 03/31/2021.
AbbVie Inc's third quarter result of 3.44 Billion USD for the item "Ebitda" represents a decrease of -20.72 percent compared to it's second quarter result.
Also, AbbVie Inc's third quarter result of 3.44 Billion USD for the item "Ebitda" represents a decrease of -29.47 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), AbbVie Inc's third quarter result of 12.72 Billion USD for the item "Ebitda" represents a decrease of -10.16 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes a decrease of -30.20 percent compared to the value the year prior.
The 1 year change in percent is -30.20.
The 3 year change in percent is -49.74.
The 5 year change in percent is -16.72.
The 10 year change in percent is 149.37.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Ebitda | 905,699,262,464.00 |
![]() | Johnson & Johnson - Ebitda | 486,508,953,600.00 |
![]() | Roche Holding AG - Ebitda | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Ebitda | 280,205,508,085.11 |
![]() | Novartis AG - Ebitda | 255,096,620,580.91 |